Rob Rodrigues

Partner

Bio

Rob Rodrigues is a seasoned litigator specializing in high-stakes business and intellectual property disputes in Brazil. Renowned for his strategic acumen, Rob delivers unmatched expertise to FORTUNE 500 companies and dynamic startups alike. He expertly navigates complex legal landscapes, ensuring robust patent portfolio management for top-tier life sciences and telecommunications firms. His deep market insight positions him as a first-choice advisor for both acquisition and enforcement actions.

Rob's excellence has been recognized by a number of leading publications. In 2024, Lexology listed him as a Legal Influencer in Dispute Resolution. Chambers describes Rob as a "superb litigator", "a very competent professional", and "outstanding in providing business-oriented advice." Who's Who Legal praises "his top-tier practice advising clients on life sciences-related patent litigation." The Legal 500 reports that clients describe Rob as someone "who stands out for his strong background in both the IP area, both in terms of litigation and in relation to more technical topics." Client testimonials in IAM Strategy 300 laud him for his "deep understanding of IP issues and keen strategic insight, which he leverages to add value and monetise portfolios."

Throughout his career, Rob has spearheaded multiple preliminary injunction proceedings and trials for global companies in Brazil. He also facilitates monumental IP asset transactions, with a keen eye on managing risks.

A Stanford Law School LL.M. alumnus, Rob served as a lead editor of the Stanford Technology Law Review. He has contributed extensively to global technology law journals and currently holds an editorial role at the Kluwer IP Blog.

Education

LL.M. in Law, Science and Technology, from Stanford Law School.

Residential Scholarship at Hoover IP2 Summer Teaching Institute.

J.D. from Universidade Federal do Rio de Janeiro (UFRJ).

Languages

Portuguese, English, Spanish

Publications

Life Sciences & Health
Life Sciences & Health

Brazilian Clinics and the False Equivalence of Compounded GLP-1 Drugs: ANVISA should follow FDA

U.S. FDA enforcement against compounded GLP-1 products highlights false equivalence claims on safety and efficacy, and Brazil faces a similar clinic-driven market—calling for ANVISA to tighten oversight, curb trademark misuse, and enforce compounding and dispensing rules.
2025
7
min read
Legal & Regulatory Updates
Legal & Regulatory Updates

Toward Leadership: How Brazil can Unlock Clinical Trials with Regulation, Transparency and Technology

Brazil can unlock leadership in clinical trials by pairing its new legal framework with clear implementing rules, better transparency tools, and technology integration—especially AI-enabled Real-World Evidence—while balancing IP protection and patient access.
2025
8
min read
Trademark & Design
Trademark & Design

Mega-Events and Intellectual Property Protection

Mega-events depend on strong IP frameworks—spanning trademarks, copyright, designs, and patents—to preserve exclusivity, curb counterfeiting and ambush marketing, and protect investments from organizers and sponsors while enabling technology used during the events.
2025
7
min read
Legal & Regulatory Updates
Legal & Regulatory Updates

Brazilian gaming market: A future look for Intellectual Property disputes

Brazil’s new gaming law (Law 14,852/2024) broadens IP protection for electronic games—linking software and devices, opening a BRPTO registration path, and foreshadowing tighter, more specialized enforcement—while court practice and international models shape the next phase for disputes.
2025
8
min read
Patent Filing & Examination
Patent Filing & Examination

BRPTO extends deadline to submit comments to new uses of known products proposed guidelines: October 27

BRPTO has extended to October 27 the public comment deadline on proposed Chemistry-chapter guidelines for new uses of known products, which tighten novelty/obviousness and enablement standards—requiring in vivo data at filing and limiting support to exactly tested compounds.
2025
5
min read